Tirzepatide FAQ: dosing, side effects, cost, and results

Last updated 2026-07-30

What is tirzepatide and how does it work?

Tirzepatide is a synthetic peptide that activates two gut hormone receptors at once: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Most older weight-loss drugs hit just one of those pathways. Tirzepatide hits both. The drug is FDA-approved under two brand names from Eli Lilly. Mounjaro is approved for type 2 diabetes management, approved in May 2022 ^[1]. Zepbound is approved for chronic weight management, approved in November 2023 ^[2]. Same molecule, same manufacturer, different indication and different box. Mechanically, activating GLP-1 and GIP receptors slows stomach emptying, increases insulin release when blood sugar is high, suppresses glucagon, and acts on brain appetite centers to reduce hunger and food noise. Patients typically describe eating less without white-knuckling it. That's the GLP-1 effect mostly; the added GIP activity seems to improve insulin sensitivity and may help preserve lean mass better than GLP-1 alone, though that second point is still being studied rather than settled fact.

How much weight can you actually lose on tirzepatide?

In SURMOUNT-1, the trial that led to FDA approval for weight management, adults with obesity or overweight without diabetes lost an average of 20.9% of body weight over 72 weeks on the 15 mg dose, compared with 3.1% on placebo ^[3]. The 5 mg group averaged 15.0% and the 10 mg group averaged 19.5% ^[3]. These are trial averages. Individual results range widely, and roughly 1 in 8 participants on the highest dose lost more than 25% of their body weight. For people with type 2 diabetes, the numbers are smaller but still substantial. SURMOUNT-2, done specifically in adults with type 2 diabetes and obesity, showed average weight loss of 14.7% at the 15 mg dose over 72 weeks compared to 3.2% for placebo ^[4]. Diabetes tends to blunt weight-loss response somewhat, a pattern seen across the whole GLP-1 class, more than tirzepatide. For a fuller breakdown by month and dose, see the tirzepatide results timeline and real-world outcome patterns in tirzepatide before and after data.

What is the standard tirzepatide dosing schedule?

Tirzepatide starts low and titrates up every four weeks. The standard schedule used in both Mounjaro and Zepbound labeling is: 2.5 mg weekly for 4 weeks (this is a starter dose, not meant for therapeutic effect), then 5 mg, then 7.5 mg, then 10 mg, then 12.5 mg, then 15 mg, each step held for at least 4 weeks ^[5]. Not everyone needs to reach 15 mg. In SURMOUNT-1, meaningful weight loss occurred at 5 mg and 10 mg too, just less of it. Prescribers often stop titrating once a patient is losing weight steadily and side effects are manageable, rather than automatically pushing to the max dose. There's no clinical rule that says you must reach 15 mg for the drug to "work." The injection is once weekly, subcutaneous (thigh, abdomen, or upper arm), same day each week, with or without food. Missing a dose by a few days is generally fine; missing more than 4 weeks usually means restarting at a lower dose because tolerance drops off. Full step-by-step titration mechanics and how to handle a missed dose deserve their own dosing guide beyond this FAQ.

What are the most common tirzepatide side effects?

Gastrointestinal side effects dominate the list. In SURMOUNT-1, the most frequently reported adverse events were nausea, diarrhea, constipation, and vomiting, occurring mostly during dose escalation and described in the trial as "mostly mild to moderate in severity" ^[3]. Nausea affected roughly 25-31% of participants across dose groups versus about 10% on placebo ^[3]. Other reported effects include decreased appetite (expected, it's part of the mechanism), abdominal pain, dyspepsia, injection site reactions, burping, and hair thinning in some users, likely related to rapid weight loss rather than a direct drug effect. Fatigue and mild dizziness get mentioned occasionally. Most GI side effects ease after the first few weeks at a given dose. The pattern that actually causes people to quit isn't usually nausea, it's constipation that doesn't resolve, or vomiting bad enough to risk dehydration. Slowing the titration schedule (staying an extra 2-4 weeks at a dose before moving up) is the most common fix prescribers use, and it works for a lot of people. Full side-effect frequency by dose, plus what helps, belongs on a dedicated safety page; this FAQ covers the headline numbers.

Who should not take tirzepatide? What are the contraindications?

Tirzepatide carries a boxed warning, the FDA's most serious label warning, for risk of thyroid C-cell tumors based on findings in rodent studies. The Zepbound label states tirzepatide is "contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)" ^[5]. Whether this risk translates to humans is unconfirmed; it's a rodent-based signal that led the FDA to require the warning as a precaution, not a demonstrated human cancer rate. Beyond that boxed warning, tirzepatide is not recommended for people with a personal history of pancreatitis without clear alternative cause, and it should be used cautiously in anyone with a history of gallbladder disease, since GLP-1 drugs are associated with a modestly increased risk of gallstones and cholecystitis, likely tied to rapid weight loss itself. It's also not studied or approved for use during pregnancy or breastfeeding, and the label recommends stopping tirzepatide at least 1 month before a planned pregnancy ^[5]. People with a history of diabetic retinopathy, severe GI disease (gastroparesis, for example), or type 1 diabetes weren't well represented in the trials that led to approval, so data on those groups is thinner. None of this is a do-it-yourself decision; a prescriber needs a full history before starting.

Mounjaro vs. Zepbound: what's actually different?

Mounjaro and Zepbound are the exact same molecule, tirzepatide, made by Eli Lilly, at the same dose strengths (2.5 mg through 15 mg). The difference is the FDA-approved indication and the label that comes with it. Mounjaro is approved specifically for improving blood sugar control in adults with type 2 diabetes, alongside diet and exercise ^[1]. Zepbound is approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition like hypertension or high cholesterol ^[2]. Insurance coverage, prior authorization rules, and even list price can differ between the two names even though the drug inside the pen is identical. A doctor can technically prescribe either one off-label for the other's use case, but insurance typically won't cover that, and pharmacies fill according to what's on the prescription. If your goal is weight loss and you don't have diabetes, Zepbound is the FDA-matched product.

Is compounded tirzepatide the same as brand-name tirzepatide?

Compounded tirzepatide is not FDA-approved. It's made by state-licensed compounding pharmacies, typically under Section 503A or by outsourcing facilities under 503B of the Federal Food, Drug, and Cosmetic Act, which allow compounding under specific conditions, including during FDA-declared drug shortages ^[6]. Tirzepatide was on the FDA's drug shortage list for an extended period, which opened the door for widespread compounding. The FDA removed tirzepatide injection products from the shortage list in December 2024 ^[7], and has since taken enforcement action against some compounders continuing to sell it, arguing the shortage-based exception no longer applies. The legal and supply landscape here has shifted multiple times and keeps shifting, so anything written today can go stale within months. Check the FDA's current drug shortage database directly if the timing matters for your decision. The active ingredient in compounded tirzepatide is supposed to be the same peptide, but compounded products are not tested or approved by the FDA for safety, efficacy, or manufacturing consistency the way Mounjaro and Zepbound are. Some compounded formulations use tirzepatide salts (like tirzepatide acetate) not used in the FDA-approved product, and the FDA has warned it cannot confirm the safety of untested salt forms ^[7]. Quality varies by pharmacy. This is the single biggest thing to understand before considering the compounded route: you're trusting a specific pharmacy's quality control, not an FDA-reviewed manufacturing process.

How much does tirzepatide cost, with or without insurance?

List price for Zepbound and Mounjaro without insurance runs around $1,000-$1,086 per month depending on dose and pharmacy, based on Lilly's published list pricing for single-dose vials and pens ^[8]. With commercial insurance and a manufacturer savings card, some patients pay as little as $25-$550 per month depending on their specific plan's coverage tier ^[8]. Medicare does not cover Zepbound for weight loss because Medicare Part D is statutorily barred from covering drugs for weight loss under current law, though Mounjaro can be covered for its diabetes indication when medically necessary. Lilly also sells lower-cost single-dose vials directly through its LillyDirect self-pay program for cash-paying patients without insurance coverage, at a lower price than the pen version, in the range of roughly $349-$499 per month depending on dose as of recent published pricing ^[8]. Prices and program terms change, so treat any specific number as approximate and check Lilly's current page before budgeting. Compounded tirzepatide is typically cheaper, often in the $200-$400 monthly range through telehealth platforms, which is the main reason people consider it despite the quality-control tradeoffs described above.

How does tirzepatide compare to semaglutide (Ozempic/Wegovy)?

The most direct comparison comes from SURMOUNT-5, a head-to-head trial published in 2025 comparing tirzepatide directly against semaglutide in adults with obesity. Tirzepatide produced significantly greater weight loss, with participants losing an average of 20.2% of body weight versus 13.7% on semaglutide over 72 weeks ^[9]. That's not a small gap. It's roughly 6.5 percentage points, which for a 220-pound person is the difference between losing about 44 pounds and losing about 30 pounds. Both drugs share a similar side effect profile (GI symptoms dominate for both), and both carry the same thyroid C-cell tumor boxed warning. Cost and insurance coverage patterns are similar too. The main practical reason someone might choose semaglutide anyway is prior response, insurance formulary restrictions, or simply that it's been on the market longer with more accumulated real-world experience. For a side-by-side breakdown across the full weight-loss drug class, more than semaglutide, see tirzepatide pros and cons.

How long does it take for tirzepatide to start working?

Appetite suppression is often noticeable within the first 1-2 weeks, even at the low 2.5 mg starter dose, though this dose isn't intended to produce significant weight loss on its own. Measurable weight loss on the scale typically starts by week 4-8 as the dose increases. In SURMOUNT-1, average weight loss reached about 5% by roughly 20 weeks and continued climbing through the full 72-week trial period without clearly plateauing at the highest dose ^[3]. That means most of the dramatic before-and-after results people share online happened over 12-18 months, not weeks. Anyone expecting a fast transformation in month one is going to be disappointed; anyone patient through the titration phase tends to see the bigger changes show up in months 4-9. A full month-by-month expectation-setting breakdown lives at tirzepatide results timeline, and aggregated real outcome data (including who tends to respond less well) is covered in tirzepatide success rate.

What happens if you stop taking tirzepatide?

Weight regain is common after stopping, because tirzepatide doesn't cure obesity, it manages an ongoing appetite and metabolic signaling issue. In the SURMOUNT-4 trial, participants who were switched from tirzepatide to placebo after an initial 36-week lead-in regained an average of 14 percentage points of body weight over the following 52 weeks, while those who stayed on tirzepatide continued to lose additional weight ^[10]. That's one of the clearest data points showing this drug's effect is not permanent once discontinued. This mirrors what's been shown with semaglutide too: it's a class effect, not something unique to tirzepatide. The practical implication is that most people considering these drugs should plan for long-term or indefinite use if the goal is to maintain the loss, similar to how a blood pressure medication works. Some patients and doctors do use a taper-and-maintain strategy at a lower dose instead of stopping outright, though there isn't strong published trial data yet on optimal long-term maintenance dosing after the SURMOUNT protocols.

Is tirzepatide worth it, and how do you decide?

That depends heavily on what you're comparing it against and how much weight loss actually changes your health risk profile. The trial evidence is strong and the FDA approvals are backed by real randomized data, not marketing claims, which distinguishes tirzepatide from a lot of weight-loss products on the market. That said, it's a long-term commitment with real costs (financial and physical), a boxed warning worth taking seriously, and a high chance of regain if stopped. People who tend to do well are those with obesity-related health conditions (type 2 diabetes, sleep apnea, hypertension) where meaningful weight loss changes disease trajectory, more than appearance. People who do less well are those looking for a quick fix without addressing the underlying eating patterns tirzepatide is meant to support, or those who can't tolerate the GI side effects even after slow titration. A full pros-and-cons breakdown, written specifically to help someone weigh this decision rather than sell it, is at is tirzepatide worth it and tirzepatide pros and cons. Real patient experience patterns, good and bad, are collected in tirzepatide reviews. If you're ready to move forward, the safest path is a provider evaluation that checks your history against the contraindications above, not a self-directed order from an unverified source. Tirz Rx's provider-reviewed process routes prescriptions through licensed pharmacy partners rather than unverified vendors, which matters a lot given the quality-control concerns around compounded tirzepatide described earlier in this article.

Frequently asked questions

Is tirzepatide the same as Ozempic?

No. Ozempic is semaglutide, a single GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) activates both GLP-1 and GIP receptors and is a different molecule made by a different company (Eli Lilly vs. Novo Nordisk). In SURMOUNT-5, tirzepatide produced greater average weight loss than semaglutide (20.2% vs 13.7% at 72 weeks) ^[10].

What is the maximum dose of tirzepatide?

The maximum approved dose is 15 mg once weekly, reached after a titration schedule that starts at 2.5 mg and increases roughly every 4 weeks through 5, 7.5, 10, and 12.5 mg ^[5]. Not everyone needs to reach the max dose; meaningful weight loss occurred at lower doses in SURMOUNT-1 too.

Can you drink alcohol on tirzepatide?

There's no formal contraindication, but alcohol can worsen nausea and GI side effects that are already common on tirzepatide, and it adds calories that work against the drug's purpose. Alcohol also affects blood sugar, which matters more for patients using it for diabetes. Most prescribers suggest minimizing intake, especially during dose increases.

Does tirzepatide cause hair loss?

Hair thinning has been reported by some users, though it's generally attributed to rapid weight loss and nutritional shifts (telogen effluvium) rather than a direct pharmacological effect of tirzepatide. This pattern is common after any significant, fast weight loss, not unique to this drug.

How is tirzepatide injected?

It's a once-weekly subcutaneous injection given in the abdomen, thigh, or upper arm, using a prefilled pen or single-dose vial with a separate syringe. It can be taken with or without food, any time of day, ideally on the same day each week for consistency.

What is the boxed warning on tirzepatide for?

Tirzepatide's boxed warning covers the risk of thyroid C-cell tumors, based on findings in rodent studies. The Zepbound label states it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[6]. Human risk hasn't been confirmed but the FDA required the warning as a precaution.

Does tirzepatide cause pancreatitis?

Acute pancreatitis has been reported in patients using tirzepatide, though it wasn't identified as a significantly elevated risk in the trials that led to approval the way it's sometimes discussed online. Anyone with a personal history of pancreatitis should discuss this specifically with their prescriber before starting.

Can you take tirzepatide without having diabetes?

Yes. Zepbound is the version FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition, regardless of diabetes status ^[2]. Mounjaro, in contrast, is approved specifically for type 2 diabetes.

Is compounded tirzepatide legal?

It can be legal when made by a licensed compounding pharmacy under specific FD&C Act provisions (Section 503A or 503B), historically tied to FDA drug shortage status ^[7]. The FDA removed tirzepatide from its drug shortage list in December 2024 ^[8], which has narrowed the legal basis for continued compounding and led to some enforcement actions since.

How much weight loss counts as a good response to tirzepatide?

Clinically, weight loss of 5% or more is considered a meaningful response, and most patients on tirzepatide exceed that. In SURMOUNT-1, average loss was 15-20.9% depending on dose over 72 weeks ^[3]. Prescribers often reassess the plan if a patient hasn't lost at least 5% by around 3 months on an adequate dose.

What should you do if tirzepatide isn't working?

First check whether the dose has been titrated high enough and long enough, since much of the weight loss in trials accumulated over 12+ months. If there's genuinely minimal response at a stable dose after several months, talk to your prescriber about dose adjustment, adherence, diet factors, or switching medications.

Does insurance cover tirzepatide?

Coverage varies widely by plan. Mounjaro is more often covered for type 2 diabetes when medically necessary. Zepbound coverage for weight loss is inconsistent, and Medicare Part D cannot cover it for weight loss under current law. Manufacturer savings cards can lower out-of-pocket costs for eligible commercially insured patients ^[9].

Sources

1. FDA, Mounjaro approval letter/label: Mounjaro (tirzepatide) approved May 2022 for type 2 diabetes
2. FDA, Zepbound approval: Zepbound approved November 2023 for chronic weight management
3. New England Journal of Medicine, SURMOUNT-1 (Jastreboff et al., 2022): 20.9% average weight loss at 15mg over 72 weeks; side effect rates; NCT04184622
4. The Lancet, SURMOUNT-2 (Garvey et al., 2023): 14.7% average weight loss in adults with type 2 diabetes at 15mg over 72 weeks
5. FDA, Zepbound prescribing information: Tirzepatide dosing schedule from 2.5mg titrating to 15mg
6. FDA, Human Drug Compounding overview of FD&C Act Sections 503A and 503B: Legal basis for pharmacy compounding under 503A and outsourcing facilities under 503B
7. FDA, Tirzepatide Injection shortage update: FDA removed tirzepatide from shortage list December 2024; warning on untested compounded salt forms
8. Eli Lilly, Zepbound/LillyDirect self-pay and savings program pricing: List price and self-pay vial pricing for Zepbound
9. Eli Lilly/NEJM, SURMOUNT-5 head-to-head trial results: Tirzepatide vs semaglutide: 20.2% vs 13.7% average weight loss at 72 weeks
10. JAMA, SURMOUNT-4 (Aronne et al., 2024): Weight regain of approximately 14 percentage points after switching from tirzepatide to placebo